Clinical trial of capecitabine combined with oxaliplatin in the treatment of advanced oesphago-gastric junction adenocarcinoma
10.13699/j.cnki.1001-6821.2016.12.010
- VernacularTitle:卡培他滨联合奥沙利铂治疗晚期食管胃交界部腺癌的临床研究
- Author:
Zhi-Li REN
1
;
Rui-Xin ZHANG
;
Xiao-Xu WU
Author Information
1. 唐山工人医院 老年科
- Keywords:
capecitabine;
oxaliplatin;
esophageal gastric junction adenocarcinoma;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(12):1088-1090
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced esophago-gastric junction adenocarcinoma.Methods Eighty patients with advanced esophago -gastric junction adenocarcinoma were random-ly divided into control group ( n=40 ) and treatment group ( n=40 ).Control group was treated with 75 mg· m-2 docetaxel, intravenous infu-sion, day 1 +20 mg· m-2 cisplatin , intravenous infusion, day 1 +750 mg· m-2 5-fluorouracil, continuous infusion for 120 h, from day 1.Treatment group was received 120 mg · m-2 oxaliplatin , intravenous infusion , qd ( after 2 weeks treatment , discontinuation 1 week ) +7.5 mg · kg -1 recombinant human endostatin , intravenous infusion , qd +2000 mg· m-2 capecitabine, oral, bid(after 2 weeks treatment, discon-tinuation 1 week).Two groups were received 3 courses of treatment , 21 d for a course.The clinical efficacy , levels of tumor specific macromole-cular glycoprotein antigen 19 -9 ( CA199 ) , cancer embryo antigen (CEA), vascular endothelial growth factor (VEGF) and cell transmembrane notch ligand 4 (DLL4), and the inci-dence of adverse drug reactions were compared between two groups.Results After treatment, the total effective rate in treatment group was significantly higher than that in control group ( 90.00% vs 72.50%, P<0.05 ).The levels of CA199, CEA, VEGF, DLL4 after treatment in two groups were significantly lower than those before treatment ( P<0.05 ) , and after treatment , these indexes in treatment group were lower than those in control group with signifi-cant difference ( P<0.05 ).The incidence of adverse drug reactions in treatment was lower than that in control group with significant difference ( 15.00% vs 32.50%, P<0.05 ).Conclusion Capecitabine combined with oxaliplatin have a definitive clinical efficacy and safety for the treatment of advanced esophago -gastric junction adenocarcinoma , which can significantly reduce the levels of CA 199, CEA, VEGF and DLL4.
